Dupilumab for Chronic Obstructive Pulmonary Disease (COPD)
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
Recruiting
Observational Study
COPD (Chronic Obstructive Pulmonary Disease)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 40 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 350 (estimated)
- Sponsor
- Sanofi · Industry
Who this trial is looking for
This trial is looking for people with Chronic Obstructive Pulmonary Disease (COPD) who are starting treatment with dupilumab. Participants will share their experiences and health information to help assess the treatment's effectiveness and safety.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with COPD.
- I am 40 years old or older.
- I am newly referred to start treatment with dupilumab.
- I have had a standard spirometry test within 90 days before joining the study.
You may not be able to join if
- I have a condition that prevents me from participating in the study.
- I have a short life expectancy.
- I am currently participating in another clinical trial.
- I have a contraindication to dupilumab.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD. Secondary objectives are to determine whether treatment with dupilumab reduces moderate and/or severe COPD exacerbations; to determine the impact of treatment on lung function …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* COPD patients who are newly referred to start dupilumab treatment
* Age ≥ 40 years
* Standard of care spirometry performed concurrently with the baseline visit or within 90 days prior to the baseline visit
Exclusion Criteria:
* Patients who have contraindication to dupilumab…
Contacts